157 related articles for article (PubMed ID: 35081748)
21. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
[TBL] [Abstract][Full Text] [Related]
22. Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.
Ghidini M; Hochster H; Doi T; Van Cutsem E; Makris L; Takahashi O; Benhadji KA; Mansoor W
Gastric Cancer; 2023 Jul; 26(4):626-637. PubMed ID: 37106214
[TBL] [Abstract][Full Text] [Related]
23. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
[TBL] [Abstract][Full Text] [Related]
26. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Shitara K; Doi T; Hosaka H; Thuss-Patience P; Santoro A; Longo F; Ozyilkan O; Cicin I; Park D; Zaanan A; Pericay C; Özgüroğlu M; Alsina M; Makris L; Benhadji KA; Ilson DH
Gastric Cancer; 2022 May; 25(3):586-597. PubMed ID: 34997449
[TBL] [Abstract][Full Text] [Related]
28. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
[TBL] [Abstract][Full Text] [Related]
29. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
Roviello G; Fancelli S; Gatta Michelet MR; Aprile G; Nobili S; Roviello F; Cianchi F; Mini E; Lavacchi D
Crit Rev Oncol Hematol; 2020 Aug; 152():102987. PubMed ID: 32485527
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer.
Zhou K; Zhou J; Zhang M; Liao W; Li Q
Clin Transl Oncol; 2020 Mar; 22(3):337-343. PubMed ID: 31041716
[TBL] [Abstract][Full Text] [Related]
31. Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Lin YL; Liu KL; Lin BR
Medicine (Baltimore); 2020 Oct; 99(43):e22780. PubMed ID: 33120790
[TBL] [Abstract][Full Text] [Related]
32. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Zaniboni A; Barone CA; Banzi MC; Bergamo F; Blasi L; Bordonaro R; Bartolomeo MD; Costanzo FD; Frassineti GL; Garufi C; Giuliani F; Latiano TP; Martinelli E; Personeni N; Racca P; Tamburini E; Tonini G; Besse MG; Spione M; Falcone A
Future Oncol; 2021 Jun; 17(18):2315-2324. PubMed ID: 33663264
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Koper A; Wileński S; Śledzińska P; Bebyn M; Koper K
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10867-10877. PubMed ID: 37318592
[TBL] [Abstract][Full Text] [Related]
34. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
Mulet N; Matos I; Noguerido A; Martini G; Élez ME; Argilés G; Tabernero J
Expert Opin Pharmacother; 2018 Apr; 19(6):623-629. PubMed ID: 29537896
[TBL] [Abstract][Full Text] [Related]
35. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
[TBL] [Abstract][Full Text] [Related]
36. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey.
Özet A; Dane F; Aykan NF; Yalçın Ş; Evrensel T; Özkan M; Karabulut B; Ormeci MN; Atasev O; Vidot L; Çiçin İ
Future Oncol; 2022 Sep; 18(29):3267-3276. PubMed ID: 36040321
[No Abstract] [Full Text] [Related]
38. Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Peeters M; Cervantes A; Moreno Vera S; Taieb J
Future Oncol; 2018 Jul; 14(16):1629-1645. PubMed ID: 29701076
[TBL] [Abstract][Full Text] [Related]
39. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
[TBL] [Abstract][Full Text] [Related]
40. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
